Bitcoin's U.S. price discount on Coinbase widened recently, with the Coinbase premium staying negative and institutional trading volume dropping sharply to 2,096.84 BTC. This suggests subdued U.S. market participation and no clear sign of renewed buying demand. Additional indicators like the VIX volatility index rising and a firm dollar add to a cautious market environment. Overall, these factors indicate that U.S. Bitcoin demand has not yet recovered.
Bitcoin's U.S. price discount and institutional trading volume provide context for the cryptocurrency market. For readers following crypto broadly, 26 of 50 major cryptocurrencies on Pluang rose while 23 fell as of Oct 26, 2026 18:21 WIB. Notable movers include SXP down 46.27%, BAL up 11.14%, and COMP down 9.80% with a 31% sell and 69% buy order split on Pluang.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
